Month: September 2026

MCDONALD, Tenn., Sept. 23, 2026 (GLOBE NEWSWIRE) — Amaero Inc. (ASX:3DA) (“Amaero” or the “Company”), a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing manufacturing of large near-net-shape components, today announced the postponement of its initial public offering due to adverse market conditions.

A Registration Statement on Form S-1 (File No. 333-298612) relating to the proposed offering of securities was filed with the U.S. Securities and Exchange Commission (the “SEC”) but has not yet been declared effective. Such securities may not be sold nor may offers to buy such securities be accepted prior to the time the registration statement is declared effective.   

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

For further information, please contact:

Amaero Inc.
Hank J. Holland
Chairman and CEO
hank.holland@amaeroinc.com

Media & Investor Enquiries in Australia
Jane Morgan
Director
jm@janemorganmanagement.com.au

Media & Investor Enquiries in United States
Shannon Devine
MZ Group
amaero@mzgroup.us

About Amaero

Amaero Inc. is a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing (“AM”) and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing manufacturing of large near-net-shape components. With manufacturing and corporate headquarters in Tennessee, we occupy a strategically critical position at the intersection of U.S. national security priorities, AM technology, and the domestic reshoring of imperative U.S. supply chains.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.

Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”).

The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation. The study evaluated the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib. The trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) compared to doublet platinum-based chemotherapy.

The SANOVO China Phase III Study has been selected for a Proffered Paper oral presentation. The study evaluated the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression. The trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy.

Details of the presentations are as follows:

Abstract title	Presenter / Lead author	Presentation details
SPONSORED STUDIES
Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results	Shun Lu (Shanghai, China)	LBA6 Presidential Symposium II Alicante Auditorium – Hall 6 Sunday, October 25, 2026 16:30 – 18:15 CEST
Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study	Yi-Long Wu (Guangzhou, China)	LBA69 Proffered paper 2: NSCLC, metastatic Alicante Auditorium – Hall 6 Monday, October 26, 2026 08:30 – 10:00 CEST
Updated results from a fruquintinib Expanded Access Program for patients with previously treated metastatic colorectal cancer	Stefan Kasper (Essen, Germany)	848P Poster Session: Colon cancer
Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving fruquintinib plus sintilimab: A post-hoc analysis of the FRUSICA-2 trial	Yuanyuan Qu (Shanghai, China)	3655eP E-poster Session: Renal cancer
Efficacy of fruquintinib plus sintilimab in special populations with advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study	Kaiwei Yang (Beijing, China)	3667eP E-poster Session: Renal cancer
Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer	Shukui Qin (Nanjing, China)	3156P Poster Session: Pancreatic cancer
INVESTIGATOR-INITIATED STUDIES
Fruquintinib plus capecitabine maintenance after first-line anti-EGFR antibody plus chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib/II study	Lin Yang/ Letian Zhang (Beijing, China)	877eP E-poster Session: Colon cancer
Real-world effectiveness and safety of fruquintinib in patients with metastatic colorectal cancer in Spain: The FrESP study	Ana Fernandez Montes (Ourense, Spain)	880eP E-poster Session: Colon cancer
CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer	Kefeng Ding (Hangzhou, China)	890eP E-poster Session: Colon cancer
A real-world study of low-dose fruquintinib combined with trifluridine/tipiracil hydrochloride (TAS-102) in the third-line and beyond treatment of metastatic colorectal cancer	Yuehong Cui/ Li Liang (Shanghai, China)	903eP E-poster Session: Colon cancer
Real-world outcomes with fruquintinib in heavily pretreated metastatic colorectal cancer: Impact of patient and disease characteristics	Maria Maddalena Laterza (Pozzuoli, Italy)	964eP E-poster Session: Colon cancer
A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 – PRODIGE115 (trials in progress)	Jean Marc Phelip (Saint-Étienne, France)	991eTiP E-poster Session: Colon cancer
Phase II study of fruquintinib plus utidelone in platinum-resistant recurrent ovarian cancer (FRUTD Trial)	Zheng Feng (Shanghai, China)	1283P Poster Session: Gynaecological cancers
Fruquintinib plus eribulin in patients with metastatic HR+, HER2–breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study	Yuan Yuan (Nanjing, China)	1896eP E-poster Session: HR+ breast cancer
Fruquintinib plus sintilimab and XELOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase II study	Hua Wang (Nanchang, China)	2980eP E-poster Session: Oesophagogastric cancer
Fruquintinib plus cadonilimab and S-1 in previously treated unresectable locally advanced or metastatic esophageal squamous cell carcinoma: preliminary efficacy and safety results from a phase Ib/II study	Huiyan Luo (Guangzhou, China)	2981eP E-poster Session: Oesophagogastric cancer
Nanoliposomal irinotecan (nal-IRI) combined with fruquintinib as second-line treatment for advanced gastric cancer: A single-arm, open-label, dose-escalation and expansion phase I/II trial	Jieer Ying/ Qi Xu (Hangzhou, China)	2986eP E-poster Session: Oesophagogastric cancer
FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma	David Tougeron (Poitiers, France)	3079eTiP E-poster Session: Oesophagogastric cancer
CHOICE III: short-course preoperative radiotherapy followed by fruquintinib plus anti–PD-1 antibody (serplulimab) for neoadjuvant treatment of pMMR/MSS mid-to-low locally advanced rectal cancer: A single-arm, single-center, prospective phase II study	Wei Zhang (Shanghai, China)	3582eTiP E-poster Session: Rectal and anal cancer
First-line fruquintinib plus serplulimab for metastatic non-clear cell renal cell carcinoma: Updated results from the phase II FRONTIER study	Jiwei Huang (Shanghai, China)	3614P Poster Session: Renal cancer
Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma	Tao Zhang/ Zhenyu Lin (Wuhan, China)	2394RO Rapid Oral Session: NETs and endocrine tumours Pamplona Auditorium – Hall 5 Friday, October 23, 2026 16:15 – 17:45 CEST
Surufatinib combined with toripalimab and nab-paclitaxel/ gemcitabine chemotherapy as first-line treatment for advanced pancreatobiliary-type ampullary carcinoma: A prospective phase II Clinical Trial	Juan Du (Nanjing, China)	507eP E-poster Session: Biliary tract cancer, incl. cholangiocarcinoma
Efficacy and safety of surufatinib in combination with CAPTEM in advanced G2/G3 Neuroendocrine Tumors: Results from a single-arm, phase II Trial	Wei Wang (Guangzhou, China)	2403P Poster Session: Neuroendocrine tumours
Surufatinib plus S-1/temozolomide as first-line therapy in MGMT-low advanced pancreatic neuroendocrine tumours (SUSTEM-p): An open-label, single-centre phase Ib/II trial	Yihebali Chi (Beijing, China)	2411P Poster Session: Neuroendocrine tumours
Updated results of a prospective, open-label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors	Ziyao Wang (Chengdu, China)	2412P  Poster Session: Neuroendocrine tumours
Matching-adjusted indirect comparison of surufatinib versus high-dose OCT-LAR in patients with advanced GEP-NETs who progressed on prior SSA Therapy	Jianming Xu (Beijing, China)	2415P Poster Session: Neuroendocrine tumours
Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study	Xiaofeng Sun (Nanjing, China)	2439eP E-poster Session: Neuroendocrine tumours
Six weeks of induction gemcitabine plus nab paclitaxel (AG) followed by sequential surufatinib plus AG or AG alone as first line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center, two cohort, phase II study	Jin Xu/ Jialin Li (Shanghai, China)	3168P Poster Session: Pancreatic cancer
A phase Ib/II study of radiotherapy combined with surufatinib and sintilimab for localized high-risk limb and trunk soft tissue sarcomas: A prospective single-center trial	Yan Wang (Shanghai, China)	3739P Poster Session: Sarcoma
Surufatinib plus serplulimab, etoposide, and carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): Updated results from a single-arm, phase Ia/Ib trial	Haipeng Xu/ Longfeng Zhang (Fuzhou, China)	3831P Poster Session: Small cell lung cancer

About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE^®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA^®.

About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS^®.

About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA^®. HUTCHMED currently retains all rights to surufatinib worldwide.

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

EssilorLuxottica and Meta further advance AI glasses category
with new products revealed at Meta Connect

The two companies introduce new line of audio AI glasses and next generation of
Ray-Ban Meta, the world’s leading AI glasses

Paris, France and Menlo Park, California (24 September 2026) – EssilorLuxottica and Meta Platforms, the partnership behind the fast-growing smart eyewear category, unveiled the next generation of AI glasses at Meta Connect. Expanding their groundbreaking portfolio of products, the companies announced a new line of audio glasses, a third generation of Ray-Ban Meta, as well as new models, features and geographies for existing products. By the end of this year, the companies will offer more than 100 different styles of AI glasses. And they announced Meta’s new personal AI agent, Muse, will be coming to AI glasses.

Ray-Ban Meta Audio: Given that audio is consistently Ray-Ban Meta’s most popular feature, particularly because the glasses deliver high-quality sound without having to close off the world around you, the companies have introduced Ray-Ban Meta Audio, a camera-free line of AI glasses, their lightest and slimmest yet, weighing as low as 43 grams, offering maximum comfort with professional-adjustable temple tips, adjustable or swappable nose pads and overextension hinges ensuring a perfect fit for all-day wear. Ray-Ban Meta Audio will launch in two new styles: Clubmaster and Burbank, both compatible with a wide range of optical prescriptions. 

Ray-Ban Meta Gen 3: Also unveiled at Meta Connect was the next generation of the world’s leading AI glasses: Ray-Ban Meta Gen 3 comes in a slimmer, more comfortable design with longer battery life and a customizable action button for instant access to Meta AI. The Gen 3 collection, which comes in 27 color and lens combinations, will now include one of the most legendary silhouettes, the Aviator, which is celebrating its 90^th anniversary, making it a milestone moment for the brand. The collection will also include Zena, a bold new style with a distinctive and modern cat eye look, and the iconic Wayfarer in both standard and large sizes.

Opening the category to new audiences: Meta Glasses with EssilorLuxottica are also expanding with two new styles – Capri and Nova – to offer a wider consumer choice and introducing also two new models designed with the international icon, LISA. These round out the most expansive and accessible portfolio of AI glasses.

A richer AI glasses experience: Muse, a personal AI agent, is coming to all the companies’ AI glasses (available in US only), handling tasks hands-free so wearers can stay present. Capture also improves with Dynamic Photo and Landscape Crop Mode, alongside support for Dolby Atmos. Finally, Hearing Enhancement (available in US only), an FDA-cleared software feature for adults with perceived mild to moderate hearing loss, arrives via one-time payment or subscription later this year. Powering the next generation of AI capabilities with consumer privacy in mind, Meta will bring “private processing” to AI glasses later this year. The portfolio of AI glasses from EssilorLuxottica and Meta will welcome new features ranging from guided workouts and nutrition, expanding navigation with cycling and public transit directions.

Global retail expansion: EssilorLuxottica is bringing the already loved portfolio of AI glasses to more consumers, expanding in the coming months in these new markets: Poland, Portugal, Israel, South Africa, Indonesia, Thailand, Hong Kong, New Zealand, Malaysia and the Philippines. Additionally, Meta Ray-Ban Display are now available to purchase online and are expanding into five new markets. The glasses go on sale today in the UK and Canada. Pre-orders will progressively start from today in France, Italy and Germany, initially through select retail locations in Vancouver, Toronto, London, Paris, Milan, Rome, Frankfurt, Hamburg and Munich.

“From launching the original Ray-Ban Stories five years ago to building a powerful assortment of AI glasses with strong consumer choice across brands, price points and tech features, we’re proud of our pioneering role in the category. As we expand with new innovations that have long been in the works like Ray-Ban Meta Audio, and develop new use cases for glasses, our ability to anticipate and deliver on consumer needs and desires will grow even stronger,” commented Francesco Milleri, Chairman and CEO, EssilorLuxottica.

“AI glasses need to match people’s individual sense of style while looking and feeling great on every kind of face. Meta and EssilorLuxottica are working to make sure every person can find the right pair for them, and the products we announced today bring new options for everyone,” said Mark Zuckerberg, CEO, Meta.

Attachment

• DOWNLOAD THE PRESS RELEASE